Loading...
XLON
APH
Market cap460mUSD
May 13, Last price  
64.70GBP
Name

Alliance Pharma PLC

Chart & Performance

D1W1MN
XLON:APH chart
P/E
—
P/S
1.96
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.39%
Rev. gr., 5y
5.69%
Revenues
179m
-1.02%
12,276,00017,253,00018,224,00021,757,00031,237,00049,881,00045,957,00044,897,00045,513,00043,536,00048,344,00097,492,000103,315,000118,208,000135,637,000129,801,000163,207,000167,416,000180,680,000178,836,000
Net income
-11m
L-67.62%
661,000503,000-3,210,0002,511,0004,107,0008,954,0008,636,0008,690,0009,584,0008,385,00012,692,00018,092,00028,910,00018,356,00025,010,0008,027,0007,319,000936,000-33,136,000-10,729,000
CFO
39m
+23.26%
360,000-910,0001,703,0002,616,0007,694,00014,895,0008,719,00012,435,00010,030,00011,423,0007,976,00016,925,00026,583,00022,170,00035,758,00041,567,00038,659,00020,972,00031,410,00038,716,000
Dividend
Jun 22, 20231.184 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
URL
https://www.alliancepharmaceuticals.com/
IPO date
Nov 22, 2001
Employees
285
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT